Compare GIFT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIFT | CALC |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0M | 7.6M |
| IPO Year | 2019 | 2020 |
| Metric | GIFT | CALC |
|---|---|---|
| Price | $0.71 | $1.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 474.4K | 73.4K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.05 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $83,181,716.00 | N/A |
| Revenue This Year | $6.02 | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $0.44 |
| 52 Week High | $1.29 | $72.00 |
| Indicator | GIFT | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 55.30 | 59.28 |
| Support Level | $0.58 | $1.00 |
| Resistance Level | $0.76 | $2.31 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 80.40 | 98.80 |
Giftify Inc operates in the incentive and rewards industry with a focus on retail, dining, and entertainment experiences, as the owner and operator of digital platforms, CardCash.com, Restaurant.com, and Takeout7.com. CardCash.com is a secondary gift card exchange platform, allowing consumers and retailers to buy and sell gift cards at various scales from several retailers; Restaurant.com is a restaurant-focused digital deals brand, connecting digital consumers and businesses by offering dining, retail, and entertainment deal options at several restaurants and retailers; and Takeout7 is a restaurant technology company offering online ordering solutions and AI-powered digital marketing services. Giftify has one segment, the sale of gift cards and discount certificates to its customers.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.